Relaxin decreases the severity of established hepatic fibrosis in mice

Liver International

Volumn 34, Issue 3, 2014, Pages 416-426

  Bennett, Robert G ^a,b,c   Heimann, Dean G ^b   Singh, Sudhir ^b   Simpson, Ronda L ^b   Tuma, Dean J ^b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Collagen; Hepatic stellate cells; Liver disease; Relaxin family peptides

Indexed keywords

CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGENASE 3; GELATINASE A; SERELAXIN; SMAD2 PROTEIN; SMOOTH MUSCLE ACTIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; COLLAGEN; MATRIX METALLOPROTEINASE; RELAXIN; SMAD2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; IN VIVO STUDY; LIVER FIBROSIS; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STELLATE CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; LIVER; LIVER CELL; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ACTINS; ANIMALS; CARBON TETRACHLORIDE; CELLS, CULTURED; COLLAGEN; HEPATIC STELLATE CELLS; HEPATOCYTES; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASES, SECRETED; MICE; MICE, INBRED C57BL; RELAXIN; SMAD2 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA;

EID: 84893793330     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12247     Document Type: Article

References (51)

1. Friedman SL. Mechanisms of hepatic fibrosis. Gastroenterology 2008; 134: 1655-69.
2. Gieling RG, Burt AD, Mann DA. Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin Liv Dis 2008; 12: 915-37.
3. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-72.
4. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Investig 2007; 117: 539-48.
5. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25: 205-34.
6. Hwang JJ, Sherwood OD. Monoclonal antibodies specific for rat relaxin III. Passive immunization with monoclonal antibodies throughout the second half of preganancy reduces cervical growth and extensibility in intact rats. Endocrinology 1988; 123: 2486-90.
7. Zhao S, Sherwood OD. Monoclonal antibodies specific for rat relaxin X. Endogenous relaxin induces changes in the histological characteristics of the rat vagina during the second half of pregnancy. Endocrinology 1998; 139: 4726-34.
8. Bennett RG. Relaxin and its role in the development and treatment of fibrosis. Transl Res 2009; 154: 1-6.
9. Heeg MH, Koziolek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005; 68: 96-109.
10. Masterson R, Hewitson TD, Kelynack K, et al. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 2004; 19: 544-52.
11. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004; 145: 4125-33.
12. Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990; 265: 10681-5.
13. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-45.
14. Garber SL, Mirochnik Y, Brecklin CS, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 2001; 59: 876-82.
15. Samuel CS, Hewitson TD, Zhang Y, Kelly DJ. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 2008; 149: 3286-93.
16. Unemori EN, Beck LS, Lee WP, et al. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 1993; 101: 280-5.
17. Zhang J, Qi Y, Geng B, et al. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 2005; 26: 1632-9.
18. Samuel CS, Zhao C, Bathgate RA, et al. The relaxin gene-knockout mouse: a model of progressive fibrosis. Ann N Y Acad Sci 2005; 1041: 173-81.
19. Du X, Samuel CS, Gao X, et al. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res 2003; 57: 395-404.
20. Williams EJ, Benyon RC, Trim N, et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001; 49: 577-83.
21. Bennett RG, Kharbanda KK, Tuma DJ. Inhibition of markers of hepatic stellate cell activation by the hormone relaxin. Biochem Pharmacol 2003; 66: 867-74.
22. Bennett RG, Dalton SR, Mahan KJ, et al. Relaxin receptors in hepatic stellate cells and cirrhotic liver. Biochem Pharmacol 2007; 73: 1033-40.
23. Bennett RG, Heimann DG, Tuma DJ. Relaxin reduces fibrosis in models of progressive and established hepatic fibrosis. Ann N Y Acad Sci 2009; 1160: 348-9.
24. Constandinou CC, Henderson N, Iredale J. Modeling liver fibrosis in rodents. In: Varga J, Brenner DA, Phan SH, eds. Fibrosis Research: Methods and Protocols. Totowa, NJ: Humana Press, 2005; 237-50.
25. Bergman I, Loxley R. Lung tissue hydrolysates: studies of the optimum conditions for the spectrophotometric determination of hydroxyproline. Analyst 1969; 94: 575-84.
26. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979; 11: 447-55.
27. Collins TJ. ImageJ for microscopy. Biotechniques 2007; 43: 25-30.
28. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23: 291-9.
29. Frederiks WM, Mook ORF. Metabolic mapping of proteinase activity with emphasis on in situ zymography of gelatinases. J Histochem Cytochem 2004; 52: 711-22.
30. Ruehl M, Muche M, Freise C, et al. Hydroxyproline-containing collagen analogs trigger the release and activation of collagen-sequestered proMMP-2 by competition with prodomain-derived peptide P33-42. Fibrogenesis Tissue Repair 2011; 4: 1-15.
31. Samuel CS, Zhao C, Bathgate RA, et al. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003; 17: 121-3.
32. Samuel CS, Zhao C, Bond CP, et al. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int 2004; 65: 2054-64.
33. Samuel CS, Zhao C, Yang Q, et al. The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol 2005; 125: 692-9.
34. Hewitson TD, Ho WY, Samuel CS. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 2010; 151: 4938-48.
35. Samuel CS, Lin F, Hossain MA, et al. Improved chemical synthesis and demonstration of the relaxin receptor binding affinity and biological activity of mouse relaxin. Biochemistry 2007; 46: 5374-81.
36. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
37. Palejwala S, Stein DE, Weiss G, et al. Relaxin positively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signaling pathway. Endocrinology 2001; 142: 3405-13.
38. Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005; 46: 412-8.
39. Iredale JP, Benyon RC, Arthur MJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996; 24: 176-84.
40. Vyas SK, Leyland H, Gentry J, Arthur MJ. Rat hepatic lipocytes synthesize and secrete transin (Stromelysin) in early primary culture. Gastroenterology 1995; 109: 889-98.
41. Benyon RC, Hovell CJ, Da Gaca M, et al. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 1999; 30: 977-86.
42. Han Y, Zhou L, Wang J, et al. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004; 279: 4820-8.
43. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. J Biol Chem 1995; 270: 5872-6.
44. Knauper V, Wilhelm SM, Seperack PK, et al. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 1993; 15: 581-6.
45. Samuel CS, Cendrawan S, Gao X, et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 2011; 91: 675-90.
46. Chow BS, Chew EG, Zhao C, et al. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS ONE 2012; 7: e42714.
47. Qin X, Garibay-Tupas J, Chua PK, Cachola L, Bryant-Greenwood GD. An autocrine/paracrine role of human decidual relaxin I. Interstitial collagenase (matrix metalloproteinase-1) and tissue plasminogen activator. Biol Reprod 1997; 56: 800-11.
48. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-31.
49. Breitkopf K, Weng H, Dooley S. TGF-beta/Smad-signaling in liver cells: target genes and inhibitors of two parallel pathways. Signal Transduction 2006; 6: 329-37.
50. Mookerjee I, Hewitson TD, Halls ML, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 2009; 23: 1219-29.
51. Hossain MA, Chow Suet Man B, Zhao C, et al. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor. Biochemistry 2011; 50: 1368-75.